ArticleCirculation research2021
Prevention of Fibrosis and Pathological Cardiac Remodeling by Salinomycin.
Open access · bronzeAbstract read
In one paragraph
Article in Circulation research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.1field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 25 citations in OpenAlex.
- New approach methodologies: drug screening platform to identify antifibrotic compounds.Nature protocols · 2026Review
- Matrifibrocytes Redefine Cardiac Fibrosis: From Terminal Differentiation to Translational Modulation.Journal of cellular and molecular medicine · 2026Review
- PD-1 inhibition disrupts collagen homeostasis and aggravates cardiac dysfunction through endothelial-fibroblast crosstalk and EndMT.Frontiers in pharmacology · 2025Article
- Article
- Review
- Hyperuricemia suppresses lumican, exacerbating adverse remodeling after myocardial infarction by promoting fibroblast phenotype transition.Journal of translational medicine · 2024Article
- Hitting the Target! Challenges and Opportunities for TGF-β Inhibition for the Treatment of Cardiac fibrosis.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Fibroblasts and immune cells: at the crossroad of organ inflammation and fibrosis.American journal of physiology. Heart and circulatory physiology · 2024Review
- Polyether Ionophore Antibiotics Target Drug-Resistant Clinical Isolates, Persister Cells, and Biofilms.Microbiology spectrum · 2023Article
- Cell-Based Phenotypic Screen for Antifibrotic Compounds Targets Eicosanoid Metabolism.Circulation research · 2023Article
- Post-myocardial infarction fibrosis: Pathophysiology, examination, and intervention.Frontiers in pharmacology · 2023Review
- New Opportunities in Heart Failure with Preserved Ejection Fraction: From Bench to Bedside… and Back.Biomedicines · 2022Review
- Transcriptional plasticity of fibroblasts in heart disease.Biochemical Society transactions · 2022Review
- Transcriptional regulation of cardiac fibroblast phenotypic plasticity.Current opinion in physiology · 2022Article
- Review
- Fibroblasts orchestrate cellular crosstalk in the heart through the ECM.Nature cardiovascular research · 2022Article
- The NLRP3 Inflammasome: Relevance in Solid Organ Transplantation.International journal of molecular sciences · 2021Review
- Cardiac Fibroblast-Specific Knockout of PGC-1α Accelerates AngII-Induced Cardiac Remodeling.Frontiers in cardiovascular medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 6 institutions in 3 countries.
Ryan M BurkeAab Cardiovascular Research Institute, Department of Medicine (R.M.B., R.A.D., P.Q., J.K.L., A.M., E.M.S.), University of Rochester School of Medicine and Dentistry, NY.
Ronald A DirkxAab Cardiovascular Research Institute, Department of Medicine (R.M.B., R.A.D., P.Q., J.K.L., A.M., E.M.S.), University of Rochester School of Medicine and Dentistry, NY.
Pearl QuijadaAab Cardiovascular Research Institute, Department of Medicine (R.M.B., R.A.D., P.Q., J.K.L., A.M., E.M.S.), University of Rochester School of Medicine and Dentistry, NY.
Janet K LighthouseAab Cardiovascular Research Institute, Department of Medicine (R.M.B., R.A.D., P.Q., J.K.L., A.M., E.M.S.), University of Rochester School of Medicine and Dentistry, NY.
Amy MohanAab Cardiovascular Research Institute, Department of Medicine (R.M.B., R.A.D., P.Q., J.K.L., A.M., E.M.S.), University of Rochester School of Medicine and Dentistry, NY.
Meghann O'BrienGenomics Research Center (M.O., W.W., J.M.A.), University of Rochester School of Medicine and Dentistry, NY.
Wojciech WojciechowskiGenomics Research Center (M.O., W.W., J.M.A.), University of Rochester School of Medicine and Dentistry, NY.
Collynn F WoellerEnvironmental Medicine (C.F.W., R.P.P.), University of Rochester School of Medicine and Dentistry, NY.
Richard P PhippsEnvironmental Medicine (C.F.W., R.P.P.), University of Rochester School of Medicine and Dentistry, NY.
Jeffrey D AlexisDepartment of Medicine (C.F.W., R.P.P., J.D.A., E.M.S.), University of Rochester School of Medicine and Dentistry, NY.
John M AshtonGenomics Research Center (M.O., W.W., J.M.A.), University of Rochester School of Medicine and Dentistry, NY.
Eric M SmallAab Cardiovascular Research Institute, Department of Medicine (R.M.B., R.A.D., P.Q., J.K.L., A.M., E.M.S.), University of Rochester School of Medicine and Dentistry, NY.
University of Rochester · USMACOM (United States) · USAlexion Pharma (Switzerland) · CHCardiovascular Institute of the South · USLighthouse Guild · USOptech (Canada) · CA
Funding
The University of Rochester's Clinical and Translational Science InstituteUL1TR002001 · NCATS · UNIVERSITY OF ROCHESTER · PI WILSON, KAREN M., ZAND, MARTIN S · 2016 to 2024
$34.6MMULTIDISCIPLINARY TRAINING IN PULMONARY RESEARCHT32HL066988 · NHLBI · UNIVERSITY OF ROCHESTER · PI GEORAS, STEVE N, O'REILLY, MICHAEL A · 2001 to 2021
$8.1MRESEARCH TRAINING IN PREVENTIVE CARDIOLOGYT32HL007937 · NHLBI · UNIVERSITY OF ROCHESTER · PI LOWENSTEIN, CHARLES J · 2000 to 2014
$7.1MRole of PKP2 in epicardial structure and functionR01HL136179 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI DELMAR, MARIO, MORLEY, GREGORY E · 2017 to 2020
$3.1MDysregulation of common metabolic and transcriptional pathways in heart and lung fibrosisR01HL133761 · NHLBI · UNIVERSITY OF ROCHESTER · PI SMALL, ERIC M, WOELLER, COLLYNN FREMONT · 2016 to 2019
$2.1MCoordination of inflammatory signaling and cardiac fibrosis by small proline rich proteinsR01HL144867 · NHLBI · UNIVERSITY OF ROCHESTER · PI SMALL, ERIC M · 2019 to 2022
$1.7MSprr2b drives cardiac fibroblast proliferation and cell cycle progression in the failing heartF32HL136066 · NHLBI · UNIVERSITY OF ROCHESTER · PI BURKE, RYAN MICHAEL · 2017 to 2018
$126kNovel mechanisms of epicardium dependent cardiac repairF32HL134206 · NHLBI · UNIVERSITY OF ROCHESTER · PI QUIJADA, PEARL JENNINE · 2016 to 2018
$122kNCATS NIH HHS UL1 TR002001NHLBI NIH HHS F32 HL134206NHLBI NIH HHS F32 HL136066NHLBI NIH HHS R01 HL133761NHLBI NIH HHS R01 HL136179NHLBI NIH HHS R01 HL144867NHLBI NIH HHS T32 HL007937NHLBI NIH HHS T32 HL066988
Abstract
[Figure: see text].
Indexed as
Extracellular MatrixAngiotensin IIAnimalsAntifibrotic AgentsCardiomegalyCell SurvivalDisease Models, AnimalFibrosisGene ExpressionHeart FailureHumansMaleMiceMice, Inbred C57BLMyocardial InfarctionMyocardiumAngiotensin IIAntifibrotic Agentsp38 Mitogen-Activated Protein KinasesPolyether PolyketidesPyransrho-Associated Kinasessalinomycinfibroblastsfibrosismicemyocardial infarctionsalinomycin
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.